WindMIL Therapeutics Appoints Dr. Kimberly Noonan as Chief Science & Technology Officer
May 06, 2021 07:00 ET | WindMIL Therapeutics
PHILADELPHIA and BALTIMORE, May 06, 2021 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs®) for cancer immunotherapy, today...
Windmil_rgb_large.png
WindMIL Therapeutics Presents New Marrow-Infiltrating Lymphocytes (MILs®) Data Demonstrating Broad Therapeutic Promise for Solid Tumor Cancers
November 09, 2020 08:00 ET | WindMIL Therapeutics
PHILADELPHIA and BALTIMORE, Nov. 09, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs®) products for cancer...
Windmil_rgb_large.png
WindMIL Therapeutics Announces Marrow-Infiltrating Lymphocytes (MILs®) Data Selected for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
October 20, 2020 07:00 ET | WindMIL Therapeutics
PHILADELPHIA and BALTIMORE, Oct. 20, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs®) products for cancer...
Windmil_rgb_large.png
WindMIL Therapeutics and Stephenson Cancer Center Announce Collaboration to Collect Bone Marrow from Patients with Renal and Urothelial Carcinomas to Develop Marrow Infiltrating Lymphocytes (MILs®)
October 13, 2020 07:00 ET | WindMIL Therapeutics
PHILADELPHIA, BALTIMORE and OKLAHOMA CITY, Oct. 13, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics (WindMIL) and Stephenson Cancer Center today announced that the first patients have been identified...
Windmil_rgb_large.png
WindMIL Therapeutics to Present at 2020 Virtual Cell & Gene Meeting on the Mesa
October 05, 2020 07:00 ET | WindMIL Therapeutics
PHILADELPHIA and BALTIMORE, Oct. 05, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs®) products for cancer...
Windmil_rgb_large.png
WindMIL Therapeutics to Present at Citi's 15th Annual BioPharma Virtual Conference
September 03, 2020 07:30 ET | WindMIL Therapeutics
PHILADELPHIA and BALTIMORE, Sept. 03, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs™) products for cancer...
Windmil_rgb_large.png
WindMIL Therapeutics Announces Dosing of First Patient in Phase 2 Clinical Study of MILs™ - NSCLC in Combination with Nivolumab (Opdivo®) for the Treatment of Non-Small Cell Lung Cancer
May 28, 2020 07:00 ET | WindMIL Therapeutics
PHILADELPHIA and BALTIMORE, May 28, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs™) products for cancer immunotherapy, today...
Windmil_rgb_large.png
WindMIL Therapeutics to Present at Jefferies Virtual Healthcare Conference 2020
May 27, 2020 07:00 ET | WindMIL Therapeutics
PHILADELPHIA and BALTIMORE, May 27, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs™) products for cancer immunotherapy, today...
Windmil_rgb_large.png
WindMIL Therapeutics to Present at UBS Virtual Global Healthcare Conference
May 12, 2020 07:00 ET | WindMIL Therapeutics
PHILADELPHIA and BALTIMORE, May 12, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs™) products for cancer immunotherapy, today...
Windmil_rgb_large.png
WindMIL Therapeutics Opens Combination Therapy Portion of its Phase 2a Clinical Trial of Marrow-Infiltrating Lymphocytes (MILs™) for Treatment of Patients with Non-Small Cell Lung Cancer
April 21, 2020 07:00 ET | WindMIL Therapeutics
PHILADELPHIA and BALTIMORE, April 21, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, today...